The serum vaspin levels are reduced in Japanese chronic hemodialysis patients

BMC Nephrology

Hirofumi Makino²  John F McDonald³  Nobuyuki Miyatake¹  Kazushi Nakao²  Shigeru Akagi²  Shoichirou Kojo²  Yuji Takatori²  Atsuko Nakatsuka²  Kazuyuki Hida²  Sanae Teshigawara²  Jun Wada²  Junko Inoue² 

[1] Department of Hygiene, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan;Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan;Millipore, Linco Research, St. Charles, MO, 63304, USA

关键词: Hemodialysis;    End-stage renal disease;    Adipokine;   

Others  :  1083049
DOI  :  10.1186/1471-2369-13-163

 received in 2011-11-18, accepted in 2012-11-27,  发布年份 2012

【 摘 要 】

Background

Visceral adipose tissue-derived serine proteinase inhibitor (vaspin) is an adipokine identified in genetically obese rats that correlates with insulin resistance and obesity in humans. Recently, we found that 7% of the Japanese population with the minor allele sequence (A) of rs77060950 exhibit higher levels of serum vaspin. We therefore evaluated the serum vaspin levels in Japanese chronic hemodialysis patients.

Methods

Healthy Japanese control volunteers (control; n = 95, 49.9±6.91 years) and Japanese patients undergoing hemodialysis therapy (HD; n = 138, 51.4±10.5 years) were enrolled in this study, and serum samples were subjected to the human vaspin RIA system.

Results

The measurement of the serum vaspin levels demonstrated that a fraction of control subjects (n = 5) and HD patients (n = 11) exhibited much higher levels (> 10 ng/ml; Vaspin_High group), while the rest of the population exhibited lower levels (< 3 ng/ml; Vaspin_Low group). By comparing the patients in the Vaspin_Low group, the serum vaspin levels were found to be significantly higher in the control subjects (0.87±0.24 ng/ml) than in the HD patients (0.32±0.15 ng/ml) (p < 0.0001). In the stepwise regression analyses, the serum creatinine and triglyceride levels were found to be independently and significantly associated with the vaspin concentrations in all subjects.

Conclusions

The creatinine levels are negatively correlated with the serum vaspin levels and were significantly reduced in the Japanese HD patients in the Vaspin_Low group.

【 授权许可】

   
2012 Inoue et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, et al.: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005, 102(30):10610-10615.
• [2]Wada J: Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008, 17(3):327-333.
• [3]Chang HM, Lee HJ, Park HS, Kang JH, Kim KS, Song YS, Jang YJ: Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity (Silver Spring) 2010, 18(11):2105-2110.
• [4]Chang HM, Park HS, Park CY, Song YS, Jang YJ: Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects. Metabolism 2010, 59(9):1276-1281.
• [5]Handisurya A, Riedl M, Vila G, Maier C, Clodi M, Prikoszovich T, Ludvik B, Prager G, Luger A, Kautzky-Willer A: Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg 2010, 20(2):198-203.
• [6]Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A: Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract 2009, 84(3):325-328.
• [7]Lee MK, Jekal Y, Im JA, Kim E, Lee SH, Park JH, Chu SH, Chung KM, Lee HC, Oh EG, et al.: Reduced serum vaspin concentrations in obese children following short-term intensive lifestyle modification. Clin Chim Acta 2010, 411(5–6):381-385.
• [8]El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI: Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011, 60(1):63-70.
• [9]Ye Y, Hou XH, Pan XP, Lu JX, Jia WP: Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J (Engl) 2009, 122(21):2530-2533.
• [10]Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, et al.: Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57(2):372-377.
• [11]Li K, Li L, Yang M, Liu H, Liu D, Yang H, Boden G, Yang G: Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity. Eur J Endocrinol 2011, 164(6):905-910.
• [12]Aust G, Richter O, Rohm S, Kerner C, Hauss J, Kloting N, Ruschke K, Kovacs P, Youn BS, Bluher M: Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009, 204(1):262-266.
• [13]Gulcelik NE, Karakaya J, Gedik A, Usman A, Gurlek A: Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009, 160(1):65-70.
• [14]Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M: Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008, 93(1):247-251.
• [15]Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, et al.: Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. J Clin Endocrinol Metab 2012, 97(7):E1202-E1207.
• [16]Breitfeld J, Tonjes A, Bottcher Y, Schleinitz D, Wiele N, Marzi C, Brockhaus C, Rathmann W, Huth C, Grallert H, et al.: Genetic variation in the vaspin gene affects circulating serum vaspin concentrations. Int J Obes (Lond) 2012.
• [17]Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. Ann Intern Med 2006, 144(1):21-28.
• [18]Ikizler TA: Resolved: being fat is good for dialysis patients: the Godzilla effect: pro. J Am Soc Nephrol 2008, 19(6):1059-1062.
• [19]Stenvinkel P, Lindholm B: Resolved: being fat is good for dialysis patients: the Godzilla effect: con. J Am Soc Nephrol 2008, 19(6):1062-1064.
• [20]Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P: The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 2010, 19(1):37-42.
• [21]Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, Wallace AM, Danesh J, Whincup PH: Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009, 53(2):167-175.
• [22]Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, Barany P, Snaedal-Jonsdottir S, Alvestrand A, Heimburger O, et al.: Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007, 85(3):695-701.
• [23]Scholze A, Rattensperger D, Zidek W, Tepel M: Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) 2007, 15(6):1617-1622.
• [24]Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005, 16(4):1091-1098.
• [25]Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, et al.: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13(1):134-141.
• [26]Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C: Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009, 76(5):567-575.
• [27]Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, Vionnet N, Rossing P: Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008, 74(5):649-654.
• [28]Hida K, Poulsen P, Teshigawara S, Nilsson E, Friedrichsen M, Ribel-Madsen R, Grunnet L, Lund SS, Wada J, Vaag A: Impact of circulating vaspin levels on metabolic variables in elderly twins. Diabetologia 2012, 55(2):530-532.
• [29]Jeong E, Youn BS, Kim DW, Kim EH, Park JW, Namkoong C, Jeong JY, Yoon SY, Park JY, Lee KU, et al.: Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J Clin Endocrinol Metab 2010, 95(4):1869-1875.
• [30]Kloting N, Kovacs P, Kern M, Heiker JT, Fasshauer M, Schon MR, Stumvoll M, Beck-Sickinger AG, Bluher M: Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 2011, 54(7):1819-1823.